



# Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly

Glenda M. MacQueen, MD, PhD<sup>1</sup>, Benicio N. Frey, MD, MSc, PhD<sup>2</sup>, Zahinoor Ismail, MD<sup>1</sup>, Natalia Jaworska, PhD<sup>3</sup>, Meir Steiner, MD, MSc, PhD<sup>2</sup>, Ryan J. Van Lieshout, MD, PhD<sup>2</sup>, Sidney H. Kennedy, MD<sup>4</sup>, Raymond W. Lam, MD<sup>5</sup>, Roumen V. Milev, MD, PhD<sup>6</sup>, Sagar V. Parikh, MD<sup>4,7</sup>, Arun V. Ravindran, MB, PhD<sup>4</sup>, and the CANMAT Depression Work Group<sup>8</sup>

## Abstract

**Background:** The Canadian Network for Mood and Anxiety Treatments (CANMAT) conducted a revision of the 2009 guidelines by updating the evidence and recommendations. The scope of the 2016 guidelines remains the management of major depressive disorder (MDD) in adults, with a target audience of psychiatrists and other mental health professionals.

**Methods:** Using the question-answer format, we conducted a systematic literature search focusing on systematic reviews and meta-analyses. Evidence was graded using CANMAT-defined criteria for level of evidence. Recommendations for lines of treatment were based on the quality of evidence and clinical expert consensus. This section on “Special Populations” is the sixth of six guidelines articles.

**Results:** Recent studies inform the treatment of MDD in children and adolescents, pregnant and breastfeeding women, women in perimenopause or menopause, and the elderly. Evidence for efficacy of treatments in these populations is more limited than for the general adult population, however, and risks of treatment in these groups are often poorly studied and reported.

**Conclusions:** Despite the limited evidence base, extant data and clinical experience suggest that each of these special populations can benefit from the systematic application of treatment guidelines for treatment of MDD.

## Keywords

major depressive disorder, clinical practice guidelines, evidence-based medicine, meta-analysis, child and adolescent psychiatry, geriatric psychiatry, maternal health, perinatal, postpartum, systematic reviews

<sup>1</sup> Department of Psychiatry, University of Calgary, Calgary, Alberta

<sup>2</sup> Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario

<sup>3</sup> Department of Psychiatry, McGill University, Montréal, Quebec

<sup>4</sup> Department of Psychiatry, University of Toronto, Toronto, Ontario

<sup>5</sup> Department of Psychiatry, University of British Columbia, Vancouver, British Columbia

<sup>6</sup> Department of Psychiatry, Queen's University, Kingston, Ontario

<sup>7</sup> Department of Psychiatry, University of Michigan, Ann Arbor, Michigan

<sup>8</sup> Members of the CANMAT Depression Work Group are listed here: [www.canmat.org/workgroups](http://www.canmat.org/workgroups).

## Corresponding Author:

Glenda M. MacQueen, MD, PhD, University of Calgary, 7D18, TRW Building, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada.  
Email: [gmmacque@ucalgary.ca](mailto:gmmacque@ucalgary.ca)

In 2009, the Canadian Network for Mood and Anxiety Treatments (CANMAT), a not-for-profit scientific and educational organization, published a revision of evidence-based clinical guidelines for the treatment of depressive disorders.<sup>1</sup> CANMAT has updated these guidelines in 2016 to reflect new evidence in the field.

The scope of these guidelines remains the management of adults with unipolar major depressive disorder (MDD), with a target audience of psychiatrists and mental health specialists. This section covers the treatment of depressive disorders in children and adolescents, women in the perinatal and menopausal stages, and the elderly, recognizing that these life stages carry distinct challenges for treatment. The section is 1 of 6 guidelines articles; other sections expand on principles of care and psychological, pharmacological, neurostimulation, and complementary and alternative medicine treatments. Treatment recommendations in this section will emphasize differences from the general guidelines for adults. These recommendations are presented as guidance for clinicians who should consider them in context of individual patients and not as standards of care.

## Methods

The full methods have been previously described,<sup>2</sup> but in summary, relevant studies in English published from January 1, 2009, to December 31, 2015, were identified using computerized searches of electronic databases (PubMed, PsychInfo, Cochrane Register of Clinical Trials), inspection of bibliographies, and review of other guidelines and major reports. Each recommendation includes the level of evidence for each graded line of treatment, using specified criteria (Table 1). The level of evidence criteria now reflect the primacy of meta-analysis because of its increasing use in the evaluation of evidence.

In special populations, consideration of harm becomes a more prominent concern than in general adult populations, because of the unique vulnerabilities of these developmental windows. The recommendations for various treatment approaches therefore reflect an attempt to balance treatment benefit and potential risks in a way that is acceptable to clinicians and patients. As studies examining harm in the treatment of MDD are often of low quality,<sup>3</sup> the confidence of the treatment recommendations in these groups may be lower than in sections focused on general adult populations. The following sections provide an overview of the treatment challenges and options for children and adolescents; pregnant, postpartum, and menopausal women; and the elderly.

## Childhood and Adolescence: A Unique Neurodevelopmental Period

In 2014, 11.4% of American youth aged 12 to 17 years reported at least 1 major depressive episode (MDE) in the past year.<sup>4</sup> Canadian statistics are limited, but 2012 Statistics Canada data found that 8.2% of surveyed youth aged 15 to

**Table 1.** Criteria for Level of Evidence and Line of Treatment.

Criteria	
Level of evidence <sup>a</sup>	
1	Meta-analysis with narrow confidence intervals and/or 2 or more RCTs with adequate sample size, preferably placebo controlled
2	Meta-analysis with wide confidence intervals and/or 1 or more RCTs with adequate sample size
3	Small-sample RCTs or nonrandomized, controlled prospective studies or case series or high-quality retrospective studies
4	Expert opinion/consensus
Line of treatment	
First line	Level 1 or Level 2 Evidence, plus clinical support <sup>b</sup>
Second line	Level 3 Evidence or higher, plus clinical support <sup>b</sup>
Third line	Level 4 Evidence or higher, plus clinical support <sup>b</sup>

RCT, randomized controlled trial.

<sup>a</sup>Note that Level 1 and 2 Evidence refer specifically to treatment studies in which randomized comparisons are available. Recommendations involving epidemiological or risk factors primarily arise from observational studies, and hence the highest level of evidence is usually Level 3. Higher order recommendations (e.g., principles of care) reflect higher level judgement of the strength of evidence from various data sources and therefore are primarily Level 4 Evidence.

<sup>b</sup>Clinical support refers to application of expert opinion of the CANMAT committees to ensure that evidence-supported interventions are feasible and relevant to clinical practice. Therefore, treatments with higher levels of evidence may be downgraded to lower lines of treatment due to clinical issues such as side effects or safety profile.

24 years reported mood disorders.<sup>5</sup> Most of the randomized-controlled trials (RCTs) of youth assess antidepressant effectiveness in 12- to 18-year-old participants, despite the rapid maturational changes during this period and the fact that a 12-year-old is developmentally distinct from an 18-year-old.<sup>6</sup> Some studies also combine children (<12 years) and adolescents (12-18 years); when recommendations are intended for a specific age group (pediatric or adolescent), this is explicitly stated.

### 6.1. What is the Initial Approach to a Child or Adolescent with Suspected Depression?

Use of standardized depression screening tools is recommended for assessing children and youth; different screening tools exist for these age groups.<sup>7,8</sup> When feasible, health care providers should use a semistructured approach to diagnostic assessment of children and adolescents who screen positive for MDD (e.g., Kiddie Schedule for Affective Disorders [K-SADS]). Given that a semistructured interview requires both time and training, this may be difficult in some settings but should be attempted (e.g., by appointing trained personnel for this purpose). Although diagnostic criteria for MDD are the same for children and adolescents, presenting symptoms may differ by age group; adolescents typically report more hypersomnia, fewer appetite and weight changes, and fewer psychotic symptoms than children.<sup>9</sup> As such, the patient's age should be taken into account when assessing

children/youth, selecting treatments, and tracking response.<sup>10</sup> Best clinical practice includes the use of various sources for diagnosis and symptom severity assessments, including a clinical interview and auxiliary information (i.e., from parents, teachers).

Supportive clinical care may be sufficient to reduce depression symptoms of a mild MDE. Supportive approaches include psychoeducation, active and empathetic listening, and lifestyle advice, including the benefits of good sleep hygiene, proper eating habits, and exercise.<sup>11</sup>

## 6.2. Is Psychotherapy an Effective Treatment for Depressed Children/Adolescents?

Previous meta-analyses found that psychotherapy, largely in the form of cognitive-behavioural therapy (CBT), confers modest antidepressant effects in depressed children/adolescents relative to comparison conditions (e.g., waitlist, minimally-treated, active placebo), with more evidence for its use in adolescents.<sup>12,13</sup> A recent review of psychotherapeutic interventions in children/adolescents (52 studies,  $N = 3805$ ) found that interpersonal therapy (IPT) retained superiority over both the short and long term compared with control interventions (waitlist, no treatment, treatment as usual, psychological placebo).<sup>14</sup> However, both CBT and IPT retained superiority over the short term compared with control conditions.<sup>14</sup> When focusing on children (8-12 years), results are mixed; 1 meta-analysis (10 RCTs,  $N = 523$ ) found CBT to be modestly superior to control conditions (largely waitlist controls), although outcome heterogeneity was sizable,<sup>15</sup> while another meta-analysis (7 RCTs) reported inconclusive evidence for the effectiveness of psychotherapy, mainly CBT, in depressed children (control: waitlist, no treatment, or medication).<sup>16</sup>

The effectiveness of Internet-based psychotherapeutic interventions in children/adolescents has also been explored. One meta-analysis found no significant benefit to Internet-based interventions in 7- to 25-year-olds on depression symptoms (although anxiety was reduced) compared with waitlist controls.<sup>17</sup> Others found that computer/Internet-based CBT in children and youth was more effective than comparison conditions (e.g., waitlist, no treatment) in alleviating depression symptoms, particularly in adolescents.<sup>18,19</sup> As such, these interventions may be a promising treatment alternative when in-person/face-to-face treatment is not feasible or available. Most Internet-based interventions have a considerable component of parental and/or teacher involvement, as well as guidance from a therapist. Therefore, Internet-based therapies may be better conceived as a piece within a therapeutic intervention strategy rather than a stand-alone approach.

A Cochrane meta-analysis (11 trials,  $N = 1307$ ) evaluated the effectiveness of psychotherapy and antidepressant medication, alone and in combination, for treating MDD in 6- to 18-year-old participants.<sup>20</sup> There were no significant group differences on most outcome measures and limited evidence favouring pharmacotherapy or combination treatment

**Table 2.** Treatment of Major Depressive Disorder in Children/Youth.

Recommendation	Treatment	Level of Evidence
First line	CBT or IPT	Level 1
	Internet-based psychotherapy (for milder severity, if in-person is not possible)	Level 1
Second line	Fluoxetine	Level 1
	Escitalopram, sertraline, citalopram <sup>a</sup>	Level 2
Third line	Venlafaxine, <sup>b</sup> TCA <sup>b</sup>	Level 2
Minimal or nonresponse		
First line	Add SSRI to psychotherapy	Level 1
Second line	Switch to another SSRI (if unresponsive to fluoxetine)	Level 2
	Venlafaxine <sup>b</sup>	Level 2
Third line	TCA <sup>b</sup>	Level 3
Treatment resistant		
First line	SSRI + psychotherapy	Level 2
Second line	Switch to another SSRI (if unresponsive to fluoxetine)	Level 2
	Venlafaxine <sup>b</sup>	Level 2
Third line	TCA <sup>b</sup>	Level 3
	Neurostimulation treatment (ECT <sup>b</sup> or rTMS <sup>b</sup> )	Level 3

Suicide/adverse events must be monitored during SSRI treatment; weekly follow-ups recommended during first 4 weeks. CBT, cognitive-behavioural therapy; ECT, electroconvulsive therapy; IPT, interpersonal therapy; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; rTMS, repetitive transcranial magnetic stimulation.

<sup>a</sup>Not recommended in those with congenital long QT syndrome, congenital heart disease, or hepatic impairment.

<sup>b</sup>Only recommended for adolescents (older than 12 years).

(vs. pharmacotherapy) in achieving remission.<sup>20</sup> Similarly, another meta-analysis (5 trials) found that CBT conferred limited additional benefit to pharmacological treatment in depressed adolescents,<sup>21</sup> but the combination did reduce functional impairment in the short term,<sup>21</sup> which is consistent with previous work.<sup>11</sup> Another Cochrane meta-analysis (9 trials,  $N = 882$ ) assessed the effectiveness of psychological and pharmacological interventions in preventing relapse or recurrence of depression after an initial episode in children and youth up to 25 years of age, and found no difference in outcomes with either approach.<sup>22</sup> Finally, CBT for suicide prevention combined with pharmacotherapy resulted in greatest improvements in depressed youth who had recently attempted suicide; these improvements appear comparable to those in nonsuicidal adolescents with MDD.<sup>23</sup>

Table 2 summarizes the treatment recommendations for MDD. In summary, as there is no clear comparative advantage for pharmacotherapy or psychotherapy in treating children/youth with non-treatment-resistant MDD, psychotherapy should be the first line of treatment in mild to moderate MDD. CBT and IPT should be considered ahead of other types of psychotherapies in treating depressed pediatric and adolescent populations.

### 6.3. What Antidepressant Medication Should Be Used in Depressed Children/Adolescents?

Selective serotonin reuptake inhibitors (SSRIs) are the most extensively studied medications for the treatment of MDD in children/youth. A Cochrane review (19 trials,  $N = 3335$ ) examined efficacy and adverse outcomes of newer generation antidepressants (SSRIs and others vs. placebo) in participants 6 to 18 years of age.<sup>24</sup> Overall, antidepressant-treated children/youth had lower depression severity scores and higher response/remission rates than placebo-treated individuals, although the effect size was small.<sup>24</sup> Fluoxetine is superior to placebo in pediatric/adolescent cohorts and is the recommended first-choice pharmacological treatment.<sup>24,25</sup> Some studies have demonstrated escitalopram superiority over placebo on functioning and depression scores,<sup>24</sup> although this may be more pronounced in adolescent cohorts rather than children.<sup>26</sup> Paroxetine has not shown efficacy in this age group.<sup>24</sup> There is some evidence that sertraline may be superior to placebo, but the effects are small; finally, there is little evidence for antidepressant effects of citalopram in children or adolescents, although remission rates tended to be higher compared with placebo.<sup>24</sup> Children/adolescents with congenital long QT syndrome should not be treated with citalopram; those with congenital heart disease or hepatic impairment should be treated with caution.<sup>27</sup>

Tricyclic antidepressants (TCAs) are not useful in treating depression in children, and there is only marginal evidence to support their use in adolescents.<sup>28</sup> Monoamine oxidase inhibitors (MAOIs) are not recommended for depressed children/youth because there has been limited assessment of MAOI effectiveness in this population and because of the side effect burden as well as potential for difficulties with the tyramine-free diet.

In summary, if psychotherapy is not accessible, acceptable, or effective, pharmacotherapy should be considered in youth with depressive episodes of moderate severity (Table 2). Pharmacotherapy should be considered as a first-line intervention in more severe cases of depression. Fluoxetine is considered a first-choice antidepressant in children/youth while escitalopram, sertraline, and, to a lesser extent, citalopram are generally considered second-choice antidepressants. Paroxetine is not recommended. TCAs and MAOIs should only be considered in treatment-resistant depression.

### 6.4. How Should Children/Adolescents Be Monitored following Initiation of Pharmacotherapy?

The United States Food and Drug Administration (FDA) recommends that patients be seen on a weekly basis during the first 4 weeks of treatment, followed by visits every 2 weeks for a month, and then after 12 weeks of treatment to monitor adverse events/suicidality.<sup>29</sup> This is especially true in more severely depressed patients, those with high suicidal ideation, and those experiencing family conflict.<sup>30</sup> The

Canadian Psychiatric Association also recommends that appointments or telephone contacts should be scheduled at least weekly within the first month of treatment for children and adolescents.<sup>31</sup> When starting antidepressant pharmacotherapy in youth, the initial dose is generally at the low end of the therapeutic range and continues for a minimum of 4 weeks before a dose increase is considered. If the patient continues to show only a partial response after 12 weeks despite adequate dosing, a change in treatment is warranted.<sup>8,9</sup>

### 6.5. How Long Should Children/Adolescents Be Treated with Pharmacotherapy?

Relatively little is known about antidepressant maintenance strategies in children/adolescents. Based primarily on adult research, maintenance treatment for 1 year or more is recommended in children/youth with a history of at least 2 depressive episodes or 1 severe or chronic episode.<sup>9</sup> In individuals with no MDD history, maintenance strategies should persist for 6 to 12 months. Antidepressant discontinuation should consist of a slow taper and occur during a relatively stress-free time (e.g., summer months).

### 6.6. How Should Treatment-resistant Depression or Comorbidity Be Approached in Children or Adolescents?

If a child/adolescent is unresponsive to first-line treatment, the possibility of a misdiagnosis (e.g., undetected bipolar disorder, comorbid medical or psychiatric disorder) should be considered prior to a treatment switch. Treatment nonadherence should also be considered, as should psychosocial factors (e.g., bullying, sexual identity concerns, and family conflict).

Based largely on findings from the Treatment of Resistant Depression in Adolescents (TORDIA) study, following an adequate course with an initial SSRI, children/adolescents showing minimal response (<20% decrease in symptoms) should be switched to another SSRI. Although participants in the TORDIA trial were equally responsive to the serotonin and norepinephrine reuptake inhibitor (SNRI) venlafaxine as to another SSRI, venlafaxine was associated with a higher rate of self-harm events in those with higher suicidal ideation; venlafaxine is therefore less preferable than switching to another SSRI.<sup>30</sup> For youth with SSRI-resistant depression, combined treatment (antidepressant + psychotherapy) decreases the number of days with depression and may be cost-effective.<sup>32</sup>

There is limited evidence for the use of neurostimulation treatments and other modalities in treating depression in pediatric/adolescent populations. Repetitive transcranial magnetic stimulation (rTMS) may hold some promise,<sup>33</sup> although large-scale randomized, sham-treatment controlled studies are lacking. Similarly, RCTs of electroconvulsive therapy (ECT) in children/adolescents are lacking, although ECT parameters in adolescents exist.<sup>34</sup> Case series indicate that ECT is effective in alleviating depression symptoms in adolescents with treatment-resistant MDD, although some

individuals did report long-term cognitive/memory impairments.<sup>35</sup> Given the potential side effect profiles and lack of evidence, ECT is not recommended in children (<12 years of age) and is only recommended with extreme caution in adolescents with treatment-resistant and severe MDD (Table 2).

Finally, the presence of a comorbid psychiatric disorder may complicate treatment. There are sparse data to guide treatment of MDD in the context of psychiatric comorbidity in individuals younger than 18 years. Some limited evidence supports the use of fluoxetine in depressed youth with mild to moderate alcohol use disorders<sup>36</sup> and with oppositional symptoms.<sup>37</sup> In the TORDIA study, remission from depression, regardless of treatment, was associated with a greater reduction in measures of anxiety, attention-deficit/hyperactivity disorder (ADHD), and oppositional symptoms.<sup>38</sup> Although the evidence is limited, treating depression in children/adolescents may reduce comorbid disorder(s) symptoms.

### 6.7. What Are the Safety Concerns for Antidepressant Medications in Children/Adolescents?

Health Canada has not approved any antidepressant medications for use in individuals younger than 18 years. Fluoxetine is the only antidepressant approved by the FDA for preadolescents (8 years and older), but both fluoxetine and escitalopram are FDA-approved for children 12 years and older.

The FDA issued a black-box warning in 2003 on SSRI use in those younger than 24 years; other regulatory agencies, including Health Canada, followed suit. The Cochrane review of newer generation antidepressants (SSRIs and others) found that median baseline risk of suicide-related outcomes (behaviour and ideation) rose from 25/1000 to 40/1000.<sup>24</sup> These results were consistent with the FDA meta-analysis that showed an ~1.5- to 2-fold risk of increased suicidal thoughts/behaviours (no suicide deaths reported) for newer antidepressants.<sup>39</sup> While epidemiological data do not demonstrate a relationship between prescriptions of antidepressants and suicide deaths in large populations of youth,<sup>40</sup> a systematic review of observational studies found a higher risk (odds ratio = 1.92) of suicidal acts (suicide and attempted suicide) with SSRI exposure in adolescents but a reduced risk in older age groups.<sup>41</sup> Given that these were observational studies, it is possible that the adolescents with SSRI exposure were more severely depressed and at higher risk of suicidality. While recognizing the risks associated with SSRI use, the consequence of untreated depression in children/adolescents is more likely to result in harm; therefore, treatment with SSRIs may be appropriate with careful monitoring.

## Perinatal Depression

Unipolar MDEs occurring during pregnancy and in the first year postpartum are frequently referred to as *perinatal depression* and are among the most common morbidities

of pregnancy and the postnatal period. The *DSM-5* defines the *peripartum onset specifier* as an MDE that emerges during pregnancy or in the first 4 weeks after delivery, an acknowledgement that up to 40% of postpartum MDEs begin during pregnancy.

Up to 7.5% of women will have a unipolar MDE during pregnancy, and 6.5% will experience one in the first 3 months postpartum. When cases of minor depressive disorder are considered, these rates increase to 18.4% and 19.2%, respectively.<sup>42,43</sup> If left untreated, MDEs can affect infant development, future depression risk, and family and vocational functioning. Timely treatment is therefore essential to optimizing outcomes for women and their families.

### 6.8. What Are the Principles of Management for Perinatal Depression?

Up to 50% of pregnancies are unplanned.<sup>44</sup> Discussions about a woman's intent to become pregnant and the safety of selected treatment strategies if a pregnancy (planned or unplanned) occurs should therefore comprise a part of the assessment and documentation of all depressed women of childbearing age.

The treatment of MDD during pregnancy and the postpartum period is marked by a number of unique challenges. These include the known risks of fetal and infant exposure to pharmacologic treatments during pregnancy and lactation, as well as those posed by untreated depression. Unfortunately, the evidence upon which our understanding of these risks is based remains limited. The *DSM-5* defines perinatal depression as a unitary diagnostic concept, but given these uncertainties and the unique risks posed by depression and its treatment during the perinatal period, we have developed separate sets of recommendations for pregnancy and the postpartum period, as well as for MDEs of mild to moderate severity, and for severe episodes. Severity of depressive episodes is defined according to the *DSM-5*.

### 6.9. How Should Depression during Pregnancy Be Treated?

Decision making around the treatment of depression during pregnancy must balance the risks associated with fetal medication exposure with those of untreated depression. Left untreated, MDEs during pregnancy are not only associated with poorer nutrition and prenatal medical care, smoking, and recreational substance misuse,<sup>45,46</sup> but also with significant suffering for women. Depression is linked to an increased risk of poor obstetrical outcomes,<sup>47</sup> small neonates for gestational age,<sup>48</sup> neonatal intensive care unit admission,<sup>49</sup> increased rates of neonatal complications,<sup>50</sup> impairments in mother-infant bonding, infant sleep difficulties,<sup>51</sup> mild developmental delays,<sup>52</sup> and cognitive, behavioural, and emotional problems in offspring.<sup>53</sup>

The recommendations for MDD in pregnancy are summarized in Table 3. The efficacy of first-line treatments for

**Table 3.** Treatment of Mild to Moderate Major Depressive Disorder during Pregnancy.

Recommendation	Treatment	Level of Evidence
First line	CBT (individual or group)	Level 1
	IPT (individual or group)	Level 1
Second line	Citalopram, escitalopram, sertraline	Level 3
Third line	Structured exercise, acupuncture (depression specific), bright-light therapy	Level 2
	Bupropion, desvenlafaxine, duloxetine	Level 3
	fluoxetine, fluvoxamine, or mirtazapine, TCAs (caution with clomipramine), venlafaxine	Level 4
	ECT (for severe, psychotic, or treatment-resistant depression)	Level 3
	Therapist-assisted Internet CBT, mindfulness-based CBT, supportive psychotherapy, couples therapy, psychodynamic psychotherapy, rTMS	Level 4
	Combination SSRI + CBT or IPT	Level 4

For severe major depressive disorder, pharmacotherapies each move up one recommendation line (e.g., second line becomes first line), despite a paucity of treatment trials in pregnant women. Psychotherapy and complementary and alternative medicine therapies as monotherapy are not recommended. ECT remains third line. CBT, cognitive-behavioural therapy; ECT, electroconvulsive therapy; IPT, interpersonal therapy; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; rTMS, repetitive transcranial magnetic stimulation.

mild to moderate depression, including CBT and IPT delivered in either individual or group format, is supported by meta-analyses.<sup>54,55</sup> Given the established efficacy of SSRIs as first-line treatments in MDD outside of the perinatal period, citalopram, escitalopram and sertraline are recommended based on efficacy and safety; combination treatment with an SSRI and CBT or IPT can also be considered. Other SSRIs (except paroxetine) and newer antidepressants are less preferred options given the relative absence of reproductive data and limited antenatal clinical use. Despite increased risks of fetal cardiovascular (CV) malformations (outlined below), paroxetine and clomipramine may be discussed with women where there is a compelling reason to consider it, such as a previous good response or ongoing stability on the medication. Doxepin should be avoided during pregnancy given its high rate of passage into breast milk and accompanying complications. MAOIs are not recommended during pregnancy given their propensity to interact with certain analgesic and anaesthetic agents. When MAOIs must be used, early consultation with anaesthesia is recommended.

Other treatments, including neurostimulation and complementary and alternative medicine strategies, can also be considered as third-line recommendations.<sup>56</sup> Recognizing the need for rapid treatment during pregnancy, interventions that have previously been effective for that woman may be worth discussing as potential second-line strategies, as long as they are not contraindicated.

In keeping with recommendations in general population samples, the use of antidepressants in the perinatal period should continue until 6 to 12 months after remission in low-risk women, although treatment for longer periods of time should be considered in those at high risk of relapse.

### 6.10. What Is the Approach to Treating Severe Depression during Pregnancy?

For severe depression during pregnancy, pharmacotherapy with particular agents is a first-choice treatment, either alone or in combination with CBT or IPT. The remaining SSRIs (except paroxetine), newer generation antidepressants, and TCAs are second line. ECT can also be considered.<sup>57</sup> Combination pharmacotherapy (see Section 3)<sup>58</sup> may be cautiously considered, but little is known about short- and long-term risks to the fetus with this approach.

### 6.11. What Are the Risks of Using Antidepressant Medications in Pregnancy?

Unfortunately, studies examining the risks of antidepressants during pregnancy are limited by the presence of exposures (e.g., maternal depression, substance or prescription misuse, poor prenatal care, maternal physical health problems) that confound associations between antidepressants and these risks. Available studies cannot fully adjust for these factors, and so the magnitude and specific nature of the risks associated with antidepressants are not completely understood.<sup>59</sup>

Most antidepressants have not been linked to an increased risk of major congenital malformations. An increased risk of CV malformations (odds ratio ~1.5) has been found with first-trimester paroxetine exposure,<sup>59</sup> although a number of these complications resolve spontaneously and do not pose significant functional impairment.<sup>60</sup> Reports have linked fluoxetine use early in pregnancy to a small increase in congenital malformations as well.<sup>61</sup> Significant evidence has not yet accrued that supports increased risks with the other SSRIs, bupropion, mirtazapine, SNRIs, or TCAs (except for clomipramine, which may be associated with an elevated risk of CV malformations). However, antidepressant risk is an active area of study, and discussions with patients should take into account the most recent data. Consultation by patients and/or physicians with Motherisk ([www.motherisk.org](http://www.motherisk.org)) can support these conversations.

There may be a very modest link between gestational SSRI use and clinically recognized spontaneous abortion (odds ratio ~1.5).<sup>62</sup> However, neither this nor the risk of malformations is in excess of the 2-fold increase in risk that is accepted as clinically significant in the field.<sup>63</sup> Studies have also linked SSRIs to a 4-day shortened gestational duration and reduced birth weight (74 grams).<sup>62</sup>

At delivery, fetuses exposed to SSRI antidepressants in the third trimester are at elevated risk of developing a syndrome of poor neonatal adaptation marked by jitteriness, irritability, tremor, respiratory distress, and excessive crying. Occurring

in 15% to 30% of infants, these symptoms are most often time-limited (typically resolving in 2-14 days), are not associated with an increased risk of mortality or longer-term neurodevelopmental problems, and resolve with supportive care.<sup>64</sup> This risk may be highest with paroxetine, venlafaxine, and fluoxetine.<sup>64</sup> Limited data also suggest that SSRIs taken late (but not early) in pregnancy may be associated with an increased risk of persistent pulmonary hypertension of the newborn (PPHN). The absolute risk is 2.9 to 3.5 per 1000 infants compared to a general population risk of 2 per 1000.<sup>65</sup>

The limited data on the longer-term postnatal effects of fetal intrauterine exposure to SSRIs report no lasting cognitive, language, emotional, or behavioural problems in offspring.<sup>66</sup> Finally, despite the fact that a small number of studies have suggested that fetal SSRI exposure may be associated with autism-spectrum disorder in offspring, these studies have significant methodological limitations, have wide confidence intervals, and require further replication before evidence-based recommendations can be made.<sup>67</sup>

### 6.12. How Is Depression Treated during the Postpartum Period?

The deleterious effects of untreated postpartum depression (PPD) on women and their families can be significant. PPD has been linked to impaired mother-infant attachment<sup>68</sup> and cognitive, emotional, and behavioural problems in offspring.<sup>69</sup> Successful treatment of maternal depression may reduce these risks.<sup>70</sup>

Breastfeeding is not contraindicated during treatment with an antidepressant medication. Concerns about breastfeeding during medication treatment include short-term adverse reactions and longer-term neurodevelopmental effects. Treatment recommendations for PPD are given for use in women who are breastfeeding. Women with PPD who are not breastfeeding should follow the general CANMAT guidelines.

For women with a mild to moderate PPD who are breastfeeding, first-line recommendations again include IPT and CBT<sup>54,55</sup> (Table 4). Second-line treatments include citalopram, escitalopram, and sertraline, which have data for effectiveness during the postpartum period, minimize risk during lactation, and pose the least known risk during the childbearing years.<sup>70</sup> Structured exercise and depression-specific acupuncture are complementary and alternative treatments that have some evidence in the postpartum period.<sup>71-73</sup> An increasing body of evidence also supports the use of therapist-assisted Internet-based behavioural activation and CBT, whereas the effectiveness of *unsupported* Internet-based psychotherapeutic interventions has not been established.<sup>74-76</sup> While not extensively studied in the postpartum period, mindfulness-based CBT and supportive, couples, and psychodynamic psychotherapy may have a role for selected women.

Despite the presence of RCT support for fluoxetine and paroxetine, they are recommended as third-line choices, the former because of its long half-life and slightly higher rates of minor adverse reactions in breastfed infants,<sup>77</sup> and the

**Table 4.** Treatment of Mild to Moderate Postpartum Depression during Breastfeeding.

Recommendation	Treatment	Level of Evidence
First line	CBT (individual or group)	Level 1
	IPT (individual or group)	Level 1
Second line	Citalopram, escitalopram, sertraline	Level 2
	Combination SSRI + CBT or IPT	Level 2
Third line	Structured exercise, acupuncture (depression specific), therapist-assisted Internet CBT, or behavioural activation	Level 2
	Fluoxetine, fluvoxamine, paroxetine TCAs (except doxepin)	Level 2
	Bupropion, desvenlafaxine, duloxetine, mirtazapine, venlafaxine, TMS, bright-light therapy	Level 3
	ECT (for severe, psychotic, or treatment-resistant depression)	Level 3
	Mindfulness-based CBT, supportive psychotherapy, couples therapy, psychodynamic psychotherapy	Level 4

For severe postpartum depression, pharmacotherapies each move up one recommendation line (e.g., second line becomes first line), despite a paucity of treatment trials in this population. Psychotherapy and complementary and alternative medicine treatments as monotherapy are not recommended. ECT remains third line. CBT, cognitive-behavioural therapy; ECT, electroconvulsive therapy; IPT, interpersonal therapy; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; TMS, transcranial magnetic stimulation.

latter because of its association with CV malformations in subsequent pregnancies. Other second-generation antidepressants are categorized as third-line treatments because of limited evidence in lactating women. Among the TCAs, nortriptyline has the most evidence in the postpartum setting and a solid track record in lactation.<sup>78</sup> Doxepin should be avoided in the postpartum period because of reports of significant adverse reactions in infants with breastfeeding.<sup>79,80</sup> Finally, rTMS<sup>79,81</sup> and bright-light therapy<sup>81,82</sup> may be effective for mild to moderate PPD.

### 6.13. What Is the Approach to Treating Severe PPD?

For severe PPD, pharmacotherapy should be used first line, with or without psychotherapy. First-choice medications are citalopram, escitalopram, and sertraline. Other antidepressants are second-choice treatments for women who are more severely depressed. ECT is also an effective treatment that is listed as third line because of its side effect profile, but it can be considered a first-choice treatment for severe depression, especially with psychosis; women can also continue to breastfeed during ECT.<sup>83</sup>

### 6.14. What Are the Risks of Antidepressants during Breastfeeding?

Exposure to antidepressants in breastfed infants is 5 to 10 times lower than exposure in utero. Serum levels in preterm

infants or those with liver and/or kidney impairment may be higher, and so consultation with a pediatrician should help guide decisions in these cases. Relative infant doses (RID) of medication <10% are generally safe, and all of the SSRIs and SNRIs tested to date appear to meet this criterion.<sup>84</sup> Sertraline, fluvoxamine, and paroxetine have the lowest RID and “milk-to-plasma” ratios. Minor reactions have been noted in case studies of over 200 infants with breastfeeding exposure to sertraline or paroxetine. Citalopram and fluoxetine have had higher rates of infant reactions (4%-5%), but these are reversible and generally limited to short-lived increases in irritability, restlessness, somnolence, or insomnia.<sup>78</sup> Given its relatively low relative infant dose, nortriptyline can be a good choice if women prefer or require treatment with a TCA. Unfortunately, next-to-no data exist on MAOIs during lactation. There is a paucity of data on the long-term neurodevelopmental outcomes of infants who receive antidepressants in breast milk, but there is currently no evidence of significant long-term neurodevelopmental effects.<sup>77</sup>

## Perimenopausal Depression

The transition to menopause (or perimenopause, the beginning of ovarian failure) starts when menstrual cycles become 7 days longer or shorter than usual and extends to the early postmenopausal years.<sup>85</sup> Perimenopause is a period of increased risk for depression compared to premenopausal years. Notably, in epidemiological studies, both increased depressive symptoms and diagnosis of an MDE occurred more frequently in perimenopausal relative to premenopausal women.<sup>86-89</sup> Perimenopause is associated with risk for both depressive recurrence and new-onset depression.<sup>87,88</sup> Along with increased rates of depression and anxiety, this period is also associated with emergence of menopausal symptoms such as hot flashes, night sweats, decreased libido, vaginal dryness, sleep disturbances, and memory complaints, all of which may negatively affect mood. Hot flashes and night sweats have been identified as independent predictors of perimenopausal depression.<sup>90</sup>

Table 5 summarizes the current evidence for treatment of MDD in perimenopausal women.

### 6.15. Is Antidepressant Medication Effective during Menopause?

Only desvenlafaxine has been specifically evaluated through randomized, placebo-controlled trials for antidepressant efficacy in peri- and postmenopausal depressed women; the 2 trials found that desvenlafaxine (50 mg daily,  $N = 434$ <sup>91</sup>; 100 mg and 200 mg daily,  $N = 387$ <sup>92</sup>) was superior to placebo. Importantly, a post-hoc analysis of these RCTs showed no differences in treatment response to desvenlafaxine between peri- and postmenopausal women.<sup>93</sup> Otherwise, small-sample, open-label studies have shown the benefit of citalopram, duloxetine, escitalopram, mirtazapine, quetiapine XR, and venlafaxine XR. There are no comparative

**Table 5.** Current Evidence for Treatment of Perimenopausal Depression.

Recommendation	Treatment	Level of Evidence
First line	Desvenlafaxine	Level 1
	CBT	Level 2
Second line	Transdermal estradiol <sup>a</sup>	Level 2
	Citalopram, duloxetine, escitalopram, mirtazapine, quetiapine XR, venlafaxine XR	Level 3
	Omega-3 fatty acids, fluoxetine, nortriptyline, paroxetine, sertraline	Level 4
	Mindfulness-based CBT, supportive psychotherapy	Level 4

CBT, cognitive-behavioural therapy.

<sup>a</sup>Women with an intact uterus should also be prescribed concomitant progesterone.

studies of antidepressants in menopausal women. Based on these limited data, the recommendations for antidepressants in peri- or postmenopausal depression do not differ from those in the general adult population.

### 6.16. Are Hormonal Agents Effective as Monotherapy or Adjunctive Treatment with Antidepressants?

Transdermal estradiol has been evaluated as both monotherapy and adjunctive posttherapy to treat perimenopausal depression. In a comparative trial of 3 hormone replacement therapies as adjuncts to venlafaxine XR in postmenopausal women, methyltestosterone but not estradiol was superior to placebo.<sup>94</sup> In 2 other small RCTs, estrogen augmentation was superior to placebo in perimenopausal women,<sup>95,96</sup> while there was no difference between transdermal estradiol and placebo in late postmenopausal women.<sup>97</sup> Hormonal agents are recommended as second-line agents for women who understand the risks and have no contraindications to hormonal therapy.

### 6.17. Are There Effective Nonpharmacologic Treatments for Depression during Menopause?

Only 1 study ( $N = 50$ ) investigated the use of CBT in perimenopausal women with depression.<sup>98</sup> Group CBT significantly decreased mean scores on the Beck Depression Inventory-II in both pre- and perimenopausal women with depression, but no change was observed in the waitlist control group. These results are consistent with a post-hoc analysis of a large open-label trial ( $N = 353$ ) showing no differences in treatment response to cognitive therapy between premenopausal, perimenopausal, and postmenopausal women.<sup>99</sup>

In contrast, adjunctive acupuncture conferred no advantage when added to self-care versus self-care alone for the



treatment of hot flashes and depressive symptoms in postmenopausal women.<sup>100</sup>

## Late-Life Depression

Late-life depression (LLD) can be defined as MDD occurring in adults 60 years and older. When discussing LLD, it is important to differentiate early adult-onset depression recurring in late life from late-onset depression. Compared to patients with earlier onset of MDD, late-onset depression has a worse prognosis, a more chronic course, a higher relapse rate, and higher levels of medical comorbidity, cognitive impairment, and mortality.<sup>101</sup> The vascular depression hypothesis posits that cerebrovascular disease predisposes, precipitates, or perpetuates some depressive syndromes in older age. This vascular burden affects fronto-striatal circuitry, resulting in depression and associated cognitive impairment, especially executive dysfunction.<sup>102,103</sup> Evidence also suggests that late-onset depression or depressive symptoms may be a prodrome for dementia; hence, monitoring of cognition at initial assessment and over time is warranted.<sup>104,105</sup>

### 6.18. What Is the Role of Nonpharmacological Treatments in LLD?

Meta-analyses have demonstrated efficacy for psychological treatments of depression in older adults,<sup>106</sup> with even higher effect sizes when minor depression and dysthymia were included.<sup>107</sup> Newer meta-analyses have addressed some methodological issues in earlier studies—namely, the need for randomization of treatment and the need to assess the effect of the type of control group on the magnitude of psychotherapy effects. A meta-analysis of 27 RCTs including 2245 participants demonstrated great variability in standardized mean differences of 0.05 to 1.36 depending on the control group.<sup>108</sup> In this meta-analysis, psychotherapies (including bibliotherapy) yielded large effects compared with waitlist and attention controls but small to moderate effects compared with supportive therapy or treatment as usual. The authors suggested that supportive therapy best controlled for the nonspecific elements of psychotherapy and should be used as the control for future studies and that problem-solving therapy (PST) has the strongest evidence base using supportive therapy as a control.<sup>108</sup> A recent meta-analysis assessed the efficacy of PST in MDD in older adults, demonstrating that PST significantly reduced depression rating scale scores and reduced disability. The authors also noted that PST is one of the few therapies studied in older people with cognitive impairment and executive dysfunction.<sup>109</sup>

### 6.19. What Are the Principles of Pharmacological Treatment of LLD?

The adage of “start low and go slow (and keep going)” is relevant in LLD. Divisions into young-old (<75 years) and

old-old ( $\geq 75$  years) can be helpful, with a greater degree of vigilance required in treating the old-old. Overall, there are pharmacokinetic changes with aging that may decrease the rate of absorption, modify bioavailability, increase half-life for lipid-soluble drugs, and increase relative concentration for water-soluble drugs and metabolites.<sup>110</sup> As comorbid medical burden and polypharmacy expand, the risk for pharmacokinetic and pharmacodynamic drug interactions increases (see Section 3).<sup>58</sup> In addition, rare antidepressant side effects in adults such as bone loss, serotonin syndrome, extrapyramidal side effects, and neuroleptic malignant syndrome are more common in the elderly.<sup>111</sup> Particular attention should be paid to falls, hyponatremia, and gastrointestinal bleeding, which are associated with SSRIs in general<sup>112,113</sup> and to QTc prolongation with citalopram.<sup>114</sup> Standard principles of conservative prescribing should be applied to minimize adverse drug outcomes.<sup>115</sup> Meta-analyses also suggest that longer antidepressant treatment trials (10-12 weeks) are required in LLD.<sup>116</sup>

### 6.20. What Is the Pharmacological Approach to LLD?

An inherent paradox in the treatment of LLD stems from the dissonance between routine clinical practice and RCT evidence. For example, while citalopram and escitalopram are generally considered by clinicians to be first-line treatments for LLD due to tolerability and fewer drug interactions,<sup>117-119</sup> none of the RCTs involving these drugs demonstrated superiority over placebo in the elderly,<sup>120-122</sup> with the exception of citalopram in a subset of old-old (>75 years) patients with severe depression (Hamilton Depression Rating Scale score > 24).<sup>120</sup> In fact, a meta-analysis of 7 studies demonstrated no difference between citalopram and other antidepressants for depression remission or trial withdrawal for adverse effects.<sup>123</sup> In contrast, geriatric clinicians are reluctant to prescribe paroxetine due to anticholinergic effects and fluoxetine due to drug interactions, yet these same SSRIs have positive RCT evidence in the treatment of LLD.<sup>124,125</sup> Thus, treatment recommendations for LLD have been evidence-informed, rather than evidence-based.<sup>119</sup>

Overall, recent systematic reviews and meta-analyses support the efficacy of antidepressants in LLD, with no difference between SSRI and SNRI classes,<sup>126</sup> and in adult-onset MDD where episodes recurred in LLD.<sup>127</sup> A subsequent meta-analysis, in adult and geriatric populations, demonstrated that antidepressants are efficacious for depression in adults 55+ years of age.<sup>128</sup> However, drug-placebo differences for studies with an entry criterion of 65+ years were modest and nonsignificant. Heterogeneity, small study number, physical comorbidity, and chronicity were all considered to affect the ability of a trial to separate drug from placebo effects.<sup>128</sup> A recent network meta-analysis, with response as an outcome (>50% reduction in depression score from baseline), demonstrated relative risks compared to placebo of greater than 1.2 for only 3 drugs: sertraline, paroxetine, and duloxetine.<sup>129</sup> A meta-analysis of moderators of

treatment response in LLD suggests older adults with longer illness duration and moderate to severe depression benefit from antidepressants compared to placebo, whereas short illness duration does not show antidepressant response.<sup>130</sup> Furthermore, executive dysfunction, especially in the subdomains of planning and organization, has been associated with poor antidepressant treatment response in LLD, which may be a factor in trial heterogeneity.<sup>131</sup> One can speculate that vascular depression, associated with executive dysfunction, may be more resistant to traditional pharmacotherapeutic approaches, and may be related to depressive syndromes that are in fact early manifestations of dementia. These are important considerations when assessing lack of response to initial treatment approaches. Among new antidepressants, vortioxetine and agomelatine have been evaluated in LLD. An RCT ( $N = 453$ ) comparing vortioxetine, duloxetine, and placebo demonstrated significant reduction of depression scores with both comparators versus placebo in adults (aged 65+ years) with depression. Additionally, both medications improved verbal learning, with vortioxetine demonstrating an additional improvement in processing speed.<sup>132</sup> Agomelatine was associated with improved depressive symptoms and better treatment response than placebo but did not separate from placebo for remission.<sup>133</sup>

There is also evidence to support efficacy of continuation and maintenance treatment in LLD. A meta-analysis of 8 double-blind RCTs found antidepressants effective in preventing relapses and recurrences in the elderly, with similar tolerability for TCAs and SSRIs.<sup>134</sup>

### 6.2.1. Is There a Role for Atypical Antipsychotic Medication in LLD?

In a post-hoc analysis pooling clinical trial data of the 61- to 67-year age group, adjunctive aripiprazole and antidepressants showed a large effect size of 0.8 compared to placebo; the most common side effects were akathisia and dizziness.<sup>135</sup> A recent National Institute of Mental Health-funded RCT ( $N = 181$ ) reported on aripiprazole augmentation (10-15 mg) in older adults (aged 60+ years) with late and early onset LLD who were nonremitters to venlafaxine XR monotherapy. For remission, aripiprazole was superior to placebo (40/91 [44%] vs. 25/90 [29%], respectively). The most common adverse events were akathisia (26%) and Parkinsonism (17%). Serious adverse events were reported in 4% of patients on aripiprazole and 2% on placebo, with 6% discontinuation on aripiprazole and 9% with placebo.<sup>136</sup>

An RCT ( $N = 338$ ) of older adults (aged 65+ years) with MDD found that quetiapine XR monotherapy (median dose 158.7 mg) demonstrated efficacy versus placebo in depression scores, response, and remission rates.<sup>137</sup> However, subgroup analysis of participants aged 75+ years demonstrated only a trend-level significance for depression score reduction ( $P = 0.068$ ). Dropout rates were 9.6% for quetiapine XR versus 4.1% for placebo.<sup>137</sup> Post-hoc analysis demonstrated

efficacy for depressive symptoms irrespective of baseline sleep, anxiety, or pain.<sup>138</sup>

When prescribed for dementia, antipsychotic medications are associated with increased risk of all-cause mortality, with greater risks for typical than atypical antipsychotics; the risk is less well elucidated in cognitively intact elderly populations.<sup>139</sup> Antipsychotic medications may be considered in selected elderly individuals, recognizing that the risk profile in cognitively intact individuals has not been confirmed.

### 6.2.2. What Is the Recommended Sequential Approach to Pharmacological Treatment of LLD?

There is support for a stepwise approach to treatment of LLD in providing the best likelihood of achieving response and remission.<sup>119</sup> In 2 large studies, IMPACT<sup>140,141</sup> and PROSPECT,<sup>142,143</sup> elderly depressed patients randomized to a stepwise algorithmic approach were much more likely to improve than if they were randomized to usual care. Specifically, the odds ratio for IMPACT versus usual care was 3.45 (response rate 45% vs. 19%;  $P < 0.001$ ), and for PROSPECT versus usual care, the odds ratio was 2.13 (likelihood of remission, 43% vs. 28%;  $P < 0.05$ ).

A systematic review and meta-analysis of treatment-resistant depression (defined as failure to respond to at least 1 treatment) in adults aged >55 years identified a dearth of randomized trial data for this patient population. Half of the participants responded to a switch or augmentation strategy, with lithium augmentation demonstrating the most consistent data for all approaches.<sup>144</sup> Of all studies included in the analysis, a sequential treatment strategy provided the highest response rates.<sup>145</sup>

For LLD, RCT data generally only assess an individual step in an algorithmic or stepwise approach. Given the challenges in interpreting the evidence in LLD, therefore, an evidence-informed sequential treatment approach is recommended, rather than simply extrapolating from individual trials (Table 6). While good clinical judgement suggests choosing antidepressants to avoid mechanisms that may be harmful in the elderly (e.g., avoiding anticholinergic antidepressants to minimize confusion and delirium risk), there is yet little evidence over the long term to support ad-hoc tailoring of antidepressant choices to target symptom clusters or to leverage specific side effects for therapeutic benefit. For example, evidence does not necessarily support that using a sedating medication to optimize sleep in a depressed patient improves overall outcomes over the course of treatment or longer. It is possible, for example, that when depression has remitted and sleep has normalized that the ongoing sedating effects of medications contribute to noncompliance or lack of tolerability. Hence, use of medications in a consistent and algorithmic manner is suggested, leveraging the extensive evidence for this approach to optimize depression outcomes.<sup>119</sup>

**Table 6.** Algorithmic Pharmacological Treatment of Late-Life Depression.

Recommendation	Treatment	Level of Evidence
First line	Duloxetine, mirtazapine, nortriptyline	Level 1
	Bupropion, citalopram/escitalopram, desvenlafaxine, duloxetine, sertraline, venlafaxine, vortioxetine	Level 2
Second line	Switch to	
	Nortriptyline	Level 1
	Moclobemide, phenelzine, quetiapine, trazodone	Level 2
	Bupropion	Level 3
	Combine with	
Aripiprazole, lithium	Level 1	
Methylphenidate	Level 2	
Third line	Switch to	
	Amitriptyline, imipramine	Level 2
	Combine SSRI or SNRI with Bupropion, SSRI	Level 3

SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.

## Summary

Depression is common across the life span. While special populations (children and youth, women in the perinatal or menopausal period, and older adults) bring unique challenges, the essential approach to depressive episodes is similar to that of the general adult population. Careful diagnosis, evidence-based evaluation of the risk-benefit ratios of specific treatment strategies, and careful monitoring of outcomes are universal elements of optimal treatment. Evidence for efficacy of treatments in these populations is often more limited than for the general population, and risks of treatment in these groups are often poorly studied and reported. Despite the limited evidence base, extant data and clinical experience suggest that each of these special populations can benefit from the systematic application of treatment guidelines for treatment of depression.

## Disclosures

The guidelines process and publication were funded entirely by internal CANMAT funds; no external support was sought or received. No honoraria were paid to authors, and no professional editorial assistance was used. All members of the CANMAT Depression Work Group disclosed potential conflicts of interest (available at [www.canmat.org](http://www.canmat.org)). CANMAT is a project-driven organization governed by a volunteer, unpaid advisory board, with no permanent staff or dedicated offices. CANMAT has a conflict of interest policy that includes disclosures by all participants, and all continuing

professional development (CPD) projects are accredited by academic institutions. CANMAT has diverse funding, but in the past 5 years (2011-2015), sources of CANMAT revenue (excluding CIHR and research funding) included national/international scientific conferences (28% of revenue), publications (26%), industry-supported CPD projects (26%), and academic projects (18%).

The CANMAT guidelines are not officially endorsed by the Canadian Psychiatric Association.

## Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article:

GMM has been on advisory boards or a speaker for Janssen, Lilly, Lundbeck, and Pfizer.

BNF has received honoraria for ad hoc speaking or advising/consulting or received research funds from Alternative Funding Plan Innovations Award, AstraZeneca, Brain & Behavioral Foundation, Bristol-Myers Squibb, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, Daiichi Sankyo, Eli Lilly, Hamilton Health Sciences Foundation, J. P. Bickell Foundation, Lundbeck, Lundbeck International Neuroscience Foundation, Ontario Brain Institute, OMHF, Ontario Ministry of Research and Innovation, NSERC, Pfizer, Servier, Society for Women's Health Research, Sunovion, and the Teresa Cascioli Charitable Foundation.

ZI has received honoraria for ad hoc speaking or advising/consulting or received research funds from Canadian Biomarker Integration Network for Depression, Canadian Consortium for Neurodegeneration and Aging, Canadian Institutes of Health Research, Janssen, Joan and Clifford Hatch Foundation, Katty Taylor Chair in Vascular Dementia, Lundbeck, National Institute of Aging, Ontario AFP Innovation Fund, Otsuka, Pfizer, and Sunovion.

NJ has no financial conflicts to declare.

MS has no financial conflicts to declare.

RJV has no financial conflicts to declare.

SHK has received honoraria for ad hoc speaking or advising/consulting or received research funds from Allergan, Brain Canada, Bristol-Myers Squibb, Canadian Institutes of Health Research, Janssen, Lundbeck, Ontario Brain Institute, Pfizer, St. Jude Medical, Servier, and Sunovion.

RWL has received honoraria for ad hoc speaking or advising/consulting or received research funds from Asia-Pacific Economic Cooperation, AstraZeneca, Brain Canada, Bristol-Myers Squibb, Canadian Institutes of Health Research, Canadian Depression Research and Intervention Network, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, Coast Capital Savings, Johnson & Johnson, Lundbeck, Lundbeck Institute, Medscape, Pfizer, St. Jude Medical, Takeda, University Health Network Foundation, and Vancouver Coastal Health Research Institute.

RVM has received speaker and consultant honoraria or research funds from Allergan, Bristol-Myers Squibb, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, Eli Lilly, Johnson & Johnson, Lallemand, Lundbeck, Merck, Ontario Brain Institute, Ontario Mental Health Foundation, Otsuka, Paladin, Pfizer, Queen's

University, Sunovion, Takeda, the University Health Network Foundation, and Valeant.

SVP has been a consultant to Bristol Myers Squibb, Lundbeck, and Takeda; has had a research contract with Assurex; and has equity in Mensante.

AVR has received speaker and consultant honoraria or research funds from Bristol-Myers Squibb, Canadian Depression Research and Intervention Network, Canadian Foundation for Innovation and the Ministry of Economic Development and Innovation, Canadian Institutes of Health Research, Grand Challenges Canada, Janssen, Lundbeck, Ontario Mental Health Foundation, Pfizer, and Sunovion.

## Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

## References

- Kennedy SH, Lam RW, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. *J Affect Disord*. 2009;117(Suppl 1): S1-S2.
- Lam RW, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: introduction and methods. *Can J Psychiatry*. 2016;61(9):506-509.
- Santaguida PL, MacQueen G, Kashavarz H, et al. Treatment for depression after unsatisfactory response to SSRIs. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012. Report No.: 12-EHC050-EF. AHRQ Comparative Effectiveness Reviews.
- Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2015. HHS Publication No. SMA 15-4927, NSDUH Series H-50.
- Pearson C, Janz T, Ali J. Mental and substance use disorders in Canada [Internet]. Ottawa (ON): Statistics Canada; 2013 [cited 2016 June 10]. Catalogue no. 82-624-X. Available from: <http://www.statcan.gc.ca/pub/82-624-x/2013001/article/11855-eng.pdf>
- Casey BJ, Jones RM, Hare TA. The adolescent brain. *Ann N Y Acad Sci*. 2008;1124:111-126.
- Stockings E, Degenhardt L, Lee YY, et al. Symptom screening scales for detecting major depressive disorder in children and adolescents: a systematic review and meta-analysis of reliability, validity and diagnostic utility. *J Affect Disord*. 2015;174:447-463.
- Lewandowski RE, Aciri MC, Hoagwood KE, et al. Evidence for the management of adolescent depression. *Pediatrics*. 2013;132:e996-e1009.
- Choe CJ, Emslie GJ, Mayes TL. Depression. *Child Adolesc Psychiatr Clin North Am*. 2012;21:807-829.
- Tao R, Emslie GJ, Mayes TL, et al. Symptom improvement and residual symptoms during acute antidepressant treatment in pediatric major depressive disorder. *J Child Adolesc Psychopharmacol*. 2010;20:423-430.
- Masi G, Liboni F, Brovedani P. Pharmacotherapy of major depressive disorder in adolescents. *Expert Opin Pharmacother*. 2010;11:375-386.
- Weisz JR, McCarty CA, Valeri SM. Effects of psychotherapy for depression in children and adolescents: a meta-analysis. *Psychol Bull*. 2006;132:132-149.
- Klein JB, Jacobs RH, Reinecke MA. Cognitive-behavioral therapy for adolescent depression: a meta-analytic investigation of changes in effect-size estimates. *J Am Acad Child Adolesc Psychiatry*. 2007;46:1403-1413.
- Zhou X, Hetrick SE, Cuijpers P, et al. Comparative efficacy and acceptability of psychotherapies for depression in children and adolescents: a systematic review and network meta-analysis. *World Psychiatry*. 2015;14:207-222.
- Arnberg A, Ost LG. CBT for children with depressive symptoms: a meta-analysis. *Cogn Behav Ther*. 2014;43:275-288.
- Forti-Buratti MA, Saikia R, Wilkinson EL, et al. Psychological treatments for depression in pre-adolescent children (12 years and younger): systematic review and meta-analysis of randomised controlled trials. *Eur Child Adolesc Psychiatry*. 2016 Mar 11. [Epub ahead of print]
- Ye X, Bapuji SB, Winters SE, et al. Effectiveness of Internet-based interventions for children, youth, and young adults with anxiety and/or depression: a systematic review and meta-analysis. *BMC Health Serv Res*. 2014;14:313.
- Ebert DD, Zarski AC, Christensen H, et al. Internet and computer-based cognitive behavioral therapy for anxiety and depression in youth: a meta-analysis of randomized controlled outcome trials. *PLoS One*. 2015;10:e0119895.
- Pennant ME, Loucas CE, Whittington C, et al. Computerised therapies for anxiety and depression in children and young people: a systematic review and meta-analysis. *Behav Res Ther*. 2015;67:1-18.
- Cox GR, Callahan P, Churchill R, et al. Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents. *Cochrane Database Syst Rev*. 2014;11:CD008324.
- Dubicka B, Elvins R, Roberts C, et al. Combined treatment with cognitive-behavioural therapy in adolescent depression: meta-analysis. *Br J Psychiatry*. 2010;197:433-440.
- Cox GR, Fisher CA, De Silva S, et al. Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents. *Cochrane Database Syst Rev*. 2012;11:CD007504.
- Vitiello B, Brent DA, Greenhill LL, et al. Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) study. *J Am Acad Child Adolesc Psychiatry*. 2009;48:997-1004.
- Hetrick SE, McKenzie JE, Cox GR, et al. Newer generation antidepressants for depressive disorders in children and adolescents. *Cochrane Database Syst Rev*. 2012;11:CD004851.

25. Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. *Lancet*. 2016 June 8. [Epub ahead of print]
26. Wagner KD, Jonas J, Findling RL, et al. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. *J Am Acad Child Adolesc Psychiatry*. 2006;45:280-288.
27. Leonard HL, March J, Rickler KC, et al. Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. *J Am Acad Child Adolesc Psychiatry*. 1997;36:725-736.
28. Hazell P, Mirzaie M. Tricyclic drugs for depression in children and adolescents. *Cochrane Database Syst Rev*. 2013;6:CD002317.
29. Adegbite-Adeniyi C, Gron B, Rowles BM, et al. An update on antidepressant use and suicidality in pediatric depression. *Expert Opin Pharmacother*. 2012;13:2119-2130.
30. Brent DA, Emslie GJ, Clarke GN, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. *Am J Psychiatry*. 2009;166:418-426.
31. Lam RW, Kennedy SH. CPA Position Statement. Prescribing antidepressants for depression in 2005: Recent concerns and recommendations. *Can J Psychiatry*. 2004; 49:11-16.
32. Lynch FL, Dickerson JF, Clarke G, et al. Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings. *Arch Gen Psychiatry*. 2011;68:253-262.
33. Donaldson AE, Gordon MS, Melvin GA, et al. Addressing the needs of adolescents with treatment resistant depressive disorders: a systematic review of rTMS. *Brain Stimul*. 2014; 7:7-12.
34. Ghaziuddin N, Kutcher SP, Knapp P, et al. Practice parameter for use of electroconvulsive therapy with adolescents. *J Am Acad Child Adolesc Psychiatry*. 2004;43:1521-1539.
35. Zhand N, Courtney DB, Flament MF. Use of electroconvulsive therapy in adolescents with treatment-resistant depressive disorders: a case series. *J ECT*. 2015;31:238-245.
36. Hirschtitt ME, Pagano ME, Christian KM, et al. Moderators of fluoxetine treatment response for children and adolescents with comorbid depression and substance use disorders. *J Subst Abuse Treat*. 2012;42:366-372.
37. Jacobs RH, Becker-Weidman EG, Reinecke MA, et al. Treating depression and oppositional behavior in adolescents. *J Clin Child Adolesc Psychol*. 2010;39:559-567.
38. Hilton RC, Rengasamy M, Mansoor B, et al. Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression. *J Am Acad Child Adolesc Psychiatry*. 2013;52:482-492.
39. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. *JAMA*. 2007;297:1683-1696.
40. Henry A, Kisicki MD, Varley C. Efficacy and safety of antidepressant drug treatment in children and adolescents. *Mol Psychiatry*. 2012;17:1186-1193.
41. Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. *CMAJ*. 2009;180:291-297.
42. Gaynes BN, Gavin N, Meltzer-Brody S, et al. Perinatal depression: prevalence, screening accuracy, and screening outcomes. *Evid Rep Technol Assess (Summ)*. 2005;119:1-8.
43. Gavin NI, Gaynes BN, Lohr KN, et al. Perinatal depression: a systematic review of prevalence and incidence. *Obstet Gynecol*. 2005;106(5, Pt 1):1071-1083.
44. Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. *Contraception*. 2011; 84:478-485.
45. Le Strat Y, Dubertret C, Le Foll B. Child marriage in the United States and its association with mental health in women. *Pediatrics*. 2011;128:524-530.
46. Zuckerman B, Amaro H, Bauchner H, et al. Depressive symptoms during pregnancy: relationship to poor health behaviors. *Am J Obstet Gynecol*. 1989;160(5, Pt 1):1107-1111.
47. Grote NK, Bridge JA, Gavin AR, et al. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. *Arch Gen Psychiatry*. 2010;67:1012-1024.
48. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. *Arch Gen Psychiatry*. 2006;63:898-906.
49. Bonari L, Pinto N, Ahn E, et al. Perinatal risks of untreated depression during pregnancy. *Can J Psychiatry*. 2004;49: 726-735.
50. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. *J Clin Psychiatry*. 2013;74:e321-e341.
51. Field T, Diego M, Hernandez-Reif M. Prenatal depression effects on the fetus and newborn: a review. *Infant Behav Dev*. 2006;29:445-455.
52. Deave T, Heron J, Evans J, et al. The impact of maternal depression in pregnancy on early child development. *BJOG*. 2008;115:1043-1051.
53. Bennett HA, Einarson A, Taddio A, et al. Depression during pregnancy: overview of clinical factors. *Clin Drug Investig*. 2004;24:157-179.
54. Sockol LE. A systematic review of the efficacy of cognitive behavioral therapy for treating and preventing perinatal depression. *J Affect Disord*. 2015;177:7-21.
55. Sockol LE, Epperson CN, Barber JP. A meta-analysis of treatments for perinatal depression. *Clin Psychol Rev*. 2011; 31:839-849.
56. Dennis CL, Dowswell T. Interventions (other than pharmacological, psychosocial or psychological) for treating antenatal depression. *Cochrane Database Syst Rev*. 2013; 7:CD006795.

57. Kim DR, Snell JL, Ewing GC, et al. Neuromodulation and antenatal depression: a review. *Neuropsychiatr Dis Treat*. 2015;11:975-982.
58. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. *Can J Psychiatry*. 2016;61(9):540-560.
59. Wurst KE, Poole C, Ephross SA, et al. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. *Birth Defects Res A Clin Mol Teratol*. 2010;88:159-170.
60. Yonkers KA, Blackwell KA, Glover J, et al. Antidepressant use in pregnant and postpartum women. *Annu Rev Clin Psychol*. 2014;10:369-392.
61. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. *J Clin Psychiatry*. 2013;74:e293-e308.
62. Ross LE, Grigoriadis S, Mamisashvili L, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. *JAMA Psychiatry*. 2013;70:436-443.
63. Einarson A, Choi J, Einarson TR, et al. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. *Can J Psychiatry*. 2009;54:242-246.
64. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. *J Clin Psychiatry*. 2013;74:e309-e320.
65. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. *BMJ*. 2014;348:f6932.
66. Nulman I, Koren G, Rovet J, et al. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. *Am J Psychiatry*. 2012;169:1165-1174.
67. Boukhris T, Sheehy O, Mottron L, et al. Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. *JAMA Pediatr*. 2016;170:117-124.
68. Moehler E, Brunner R, Wiebel A, et al. Maternal depressive symptoms in the postnatal period are associated with long-term impairment of mother-child bonding. *Arch Womens Ment Health*. 2006;9:273-278.
69. O'Hara MW, McCabe JE. Postpartum depression: current status and future directions. *Annu Rev Clin Psychol*. 2013;9:379-407.
70. Molyneaux E, Howard LM, McGeown HR, et al. Antidepressant treatment for postnatal depression. *Cochrane Database Syst Rev*. 2014;9:CD002018.
71. Daley A, Jolly K, MacArthur C. The effectiveness of exercise in the management of post-natal depression: systematic review and meta-analysis. *Fam Pract*. 2009;26:154-162.
72. Daley AJ, Blamey RV, Jolly K, et al. A pragmatic randomized controlled trial to evaluate the effectiveness of a facilitated exercise intervention as a treatment for postnatal depression: the PAM-PeRS trial. *Psychol Med*. 2015;45:2413-2425.
73. Brandon AR, Crowley SK, Gordon JL, et al. Nonpharmacologic treatments for depression related to reproductive events. *Curr Psychiatry Rep*. 2014;16:526.
74. O'Mahen HA, Richards DA, Woodford J, et al. Netmums: a phase II randomized controlled trial of a guided Internet behavioural activation treatment for postpartum depression. *Psychol Med*. 2014;44:1675-1689.
75. O'Mahen HA, Woodford J, McGinley J, et al. Internet-based behavioral activation—treatment for postnatal depression (Netmums): a randomized controlled trial. *J Affect Disord*. 2013;150:814-822.
76. Pugh NE, Hadjistavropoulos HD, Dirkse D. A randomised controlled trial of therapist-assisted, Internet-delivered cognitive behavior therapy for women with maternal depression. *PLoS One*. 2016;11:e0149186.
77. Orsolini L, Bellantuono C. Serotonin reuptake inhibitors and breastfeeding: a systematic review. *Hum Psychopharmacol*. 2015;30:4-20.
78. Wisner KL, Hanusa BH, Perel JM, et al. Postpartum depression: a randomized trial of sertraline versus nortriptyline. *J Clin Psychopharmacol*. 2006;26:353-360.
79. Garcia KS, Flynn P, Pierce KJ, et al. Repetitive transcranial magnetic stimulation treats postpartum depression. *Brain Stimul*. 2010;3:36-41.
80. Moretti ME. Psychotropic drugs in lactation—Motherisk Update 2008. *Can J Clin Pharmacol*. 2009;16:e49-e57.
81. Crowley SK, Youngstedt SD. Efficacy of light therapy for perinatal depression: a review. *J Physiol Anthropol*. 2012;31:15.
82. Gressier F, Rotenberg S, Ait Tayeb AE, et al. Tobacco consumption concerns with the use of CYP1A2 metabolized antidepressants. *Am J Psychiatry*. 2015;172:909-910.
83. Gressier F, Rotenberg S, Cazas O, et al. Postpartum electroconvulsive therapy: a systematic review and case report. *Gen Hosp Psychiatry*. 2015;37:310-314.
84. Kim DR, Epperson CN, Weiss AR, et al. Pharmacotherapy of postpartum depression: an update. *Expert Opin Pharmacother*. 2014;15:1223-1234.
85. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. *Climacteric*. 2012;15:105-114.
86. Bromberger JT, Matthews KA, Schott LL, et al. Depressive symptoms during the menopausal transition: the Study of Women's Health Across the Nation (SWAN). *J Affect Disord*. 2007;103(1-3):267-272.
87. Cohen LS, Soares CN, Vitonis AF, et al. Risk for new onset of depression during the menopausal transition: the Harvard

- study of moods and cycles. *Arch Gen Psychiatry*. 2006;63:385-390.
88. Freeman EW, Sammel MD, Lin H, et al. Associations of hormones and menopausal status with depressed mood in women with no history of depression. *Arch Gen Psychiatry*. 2006;63:375-382.
89. Woods NF, Smith-DiJulio K, Percival DB, et al. Depressed mood during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study. *Menopause*. 2008;15(2):223-232.
90. Frey BN, Lord C, Soares CN. Depression during menopausal transition: a review of treatment strategies and pathophysiological correlates. *Menopause Int*. 2008;14:123-128.
91. Clayton AH, Kornstein SG, Dunlop BW, et al. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. *J Clin Psychiatry*. 2013;74:1010-1017.
92. Kornstein SG, Jiang Q, Reddy S, et al. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. *J Clin Psychiatry*. 2010;71:1088-1096.
93. Kornstein SG, Clayton AH, Bao W, et al. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women. *J Womens Health (Larchmt)*. 2015;24:281-290.
94. Dias RS, Kerr-Corrêa F, Moreno RA. Efficacy of hormone therapy with and without methyltestosterone augmentation of venlafaxine in the treatment of postmenopausal depression: a double-blind controlled pilot study. *Menopause*. 2006;13:202-211.
95. Soares CN, Almeida OP, Joffe H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. *Arch Gen Psychiatry*. 2001;58:529-534.
96. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. *Am J Obstet Gynecol*. 2000;183:414-420.
97. Morrison MF, Kallan MJ, Ten Have T, et al. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. *Biol Psychiatry*. 2004;55:406-412.
98. Khoshbooi R, Hassan SA, Hamzah MSG, et al. Effectiveness of group cognitive behavioral therapy on depression among Iranian women around menopause. *Aust J Basic Appl Sci*. 2011;5:991-995.
99. Brandon AR, Minhajuddin A, Thase ME, et al. Impact of reproductive status and age on response of depressed women to cognitive therapy. *J Womens Health (Larchmt)*. 2013;22:58-66.
100. Dørmænen A, Heimdal MR, Wang CE, et al. Depression in postmenopause: a study on a subsample of the Acupuncture on Hot Flashes Among Menopausal Women (ACUFLASH) study. *Menopause*. 2011;18:525-530.
101. Ismail Z, Fischer C, McCall WV. What characterizes late-life depression? *Psychiatr Clin North Am*. 2013;36:483-496.
102. Alexopoulos GS, Meyers BS, Young RC, et al. 'Vascular depression' hypothesis. *Arch Gen Psychiatry*. 1997;54:915-922.
103. Krishnan KR, Taylor WD, McQuoid DR, et al. Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression. *Biol Psychiatry*. 2004;55:390-397.
104. Ismail Z, Malick A, Smith EE, et al. Depression versus dementia: is this construct still relevant? *Neurodegener Dis Manag*. 2014;4:119-126.
105. Ismail Z, Smith EE, Geda Y, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. *Alzheimers Dement*. 2016;12:195-202.
106. Cuijpers P, van Straten A, Smit F. Psychological treatment of late-life depression: a meta-analysis of randomized controlled trials. *Int J Geriatr Psychiatry*. 2006;21:1139-1149.
107. Pinquart M, Duberstein PR, Lyness JM. Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy. *Am J Psychiatry*. 2006;163:1493-1501.
108. Huang AX, Delucchi K, Dunn LB, et al. A systematic review and meta-analysis of psychotherapy for late-life depression. *Am J Geriatr Psychiatry*. 2015;23:261-273.
109. Kirkham JG, Choi N, Seitz DP. Meta-analysis of problem solving therapy for the treatment of major depressive disorder in older adults. *Int J Geriatr Psychiatry*. 2016;31:526-535.
110. Ismail Z, Pollock BG. General principles of pharmacologic therapy. In: Tasman A, Kay J, Lieberman JA, First MB, Maj M, editors. *Psychiatry*. 3rd ed. Chichester (UK): John Wiley; 2008. pp. 2097-2111.
111. Topiwala A, Chouliaras L, Ebmeier KP. Prescribing selective serotonin reuptake inhibitors in older age. *Maturitas*. 2014;77:118-123.
112. De Picker L, Van Den Eede F, Dumont G, et al. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. *Psychosomatics*. 2014;55:536-547.
113. Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. *BMJ*. 2011;343:d4551.
114. Cooke MJ, Waring WS. Citalopram and cardiac toxicity. *Eur J Clin Pharmacol*. 2013;69:755-760.
115. Schiff GD, Galanter WL, Duhig J, et al. Principles of conservative prescribing. *Arch Intern Med*. 2011;171:1433-1440.
116. Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. *Am J Geriatr Psychiatry*. 2008;16:558-567.
117. Alexopoulos GS, Katz IR, Reynolds CF III, et al. The expert consensus guideline series: pharmacotherapy of depressive disorders in older patients. *Postgrad Med*. 2001 Oct; Spec No Pharmacotherapy:1-86.
118. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health—the assessment and

- treatment of depression [Internet]. 2006. Available from: <http://www.ccsmh.ca/en/guidelinesUsers.cfm>
119. Mulsant BH, Blumberger DM, Ismail Z, et al. A systematic approach to pharmacotherapy for geriatric major depression. *Clin Geriatr Med*. 2014;30:517-534.
  120. Roose SP, Sackeim HA, Krishnan KR, et al. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. *Am J Psychiatry*. 2004;161:2050-2059.
  121. Bose A, Li D, Gandhi C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. *Am J Geriatr Psychiatry*. 2008;16:14-20.
  122. Kasper S, de Swart H, Friis Andersen H. Escitalopram in the treatment of depressed elderly patients. *Am J Geriatr Psychiatry*. 2005;13:884-891.
  123. Seitz DP, Gill SS, Conn DK. Citalopram versus other antidepressants for late-life depression: a systematic review and meta-analysis. *Int J Geriatr Psychiatry*. 2010;25:1296-1305.
  124. Tollefson GD, Bosomworth JC, Heiligenstein JH, et al. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group. *Int Psychogeriatr*. 1995;7:89-104.
  125. Rapaport MH, Schneider LS, Dunner DL, et al. Efficacy of controlled-release paroxetine in the treatment of late-life depression. *J Clin Psychiatry*. 2003;64:1065-1074.
  126. Mukai Y, Tampi RR. Treatment of depression in the elderly: a review of the recent literature on the efficacy of single-versus dual-action antidepressants. *Clin Ther*. 2009;31:945-961.
  127. Kok RM, Nolen WA, Heeren TJ. Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. *J Affect Disord*. 2012;141:103-115.
  128. Tedeschini E, Levkovitz Y, Iovieno N, et al. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. *J Clin Psychiatry*. 2011;72:1660-1668.
  129. Thorlund K, Druyts E, Wu P, et al. Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. *J Am Geriatr Soc*. 2015;63:1002-1009.
  130. Nelson JC, Delucchi KL, Schneider LS. Moderators of outcome in late-life depression: a patient-level meta-analysis. *Am J Psychiatry*. 2013;170:651-659.
  131. Pimontel MA, Rindskopf D, Rutherford BR, et al. A meta-analysis of executive dysfunction and antidepressant treatment response in late-life depression. *Am J Geriatr Psychiatry*. 2016;24:31-41.
  132. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. *Int Clin Psychopharmacol*. 2012;27:215-223.
  133. Heun R, Ahokas A, Boyer P, et al. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. *J Clin Psychiatry*. 2013;74:587-594.
  134. Kok RM, Heeren TJ, Nolen WA. Continuing treatment of depression in the elderly: a systematic review and meta-analysis of double-blinded randomized controlled trials with antidepressants. *Am J Geriatr Psychiatry*. 2011;19:249-255.
  135. Steffens DC, Nelson JC, Eudicone JM, et al. Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. *Int J Geriatr Psychiatry*. 2011;26:564-572.
  136. Lenze EJ, Mulsant BH, Blumberger DM, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2015;386:2404-2412.
  137. Katila H, Mezhebovsky I, Mulroy A, et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. *Am J Geriatr Psychiatry*. 2013;21:769-784.
  138. Montgomery SA, Altamura AC, Katila H, et al. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels. *Int Clin Psychopharmacol*. 2014;29:93-105.
  139. Gareri P, Segura-Garcia C, Manfredi VG, et al. Use of atypical antipsychotics in the elderly: a clinical review. *Clin Interv Aging*. 2014;9:1363-1373.
  140. Unützer J, Katon W, Callahan CM, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. *JAMA*. 2002;288:2836-2845.
  141. Unützer J, Katon W, Williams JW Jr, et al. Improving primary care for depression in late life: the design of a multicenter randomized trial. *Med Care*. 2001;39:785-799.
  142. Mulsant BH, Alexopoulos GS, Reynolds CF III, et al. Pharmacological treatment of depression in older primary care patients: the PROSPECT algorithm. *Int J Geriatr Psychiatry*. 2001;16:585-592.
  143. Alexopoulos GS, Katz IR, Bruce ML, et al. Remission in depressed geriatric primary care patients: a report from the PROSPECT study. *Am J Psychiatry*. 2005;162:718-724.
  144. Cooper C, Katona C, Lyketsos K, et al. A systematic review of treatments for refractory depression in older people. *Am J Psychiatry*. 2013;168:681-688.
  145. Kok RM, Nolen WA, Heeren TJ. Outcome of late-life depression after 3 years of sequential treatment. *Acta Psychiatr Scand*. 2009;119:274-281.